Longitudinal Changes in Sarcopenia Was Associated with Survival Among Cirrhotic Patients

Overview

Journal Front Nutr

Specialty Nutritional Sciences

Date 2024 Jun 14

PMID 38873566

Authors

Minjie Jiang

Xin Hua

Muchen Wu

Jing Wu

Xiaotong Xu

Juan Li

Qinghua Meng

Affiliations

Soon will be listed here.

Abstract

Background: Sarcopenia is common in patients with liver cirrhosis and is an independent predictor of multiple clinical outcomes. Most studies to date have used a static assessment of sarcopenia. However, there is very limited data evaluating the temporal course of muscle area in cirrhosis. To bridge this gap in clinical studies, we performed a longitudinal analysis to evaluate the impact of changes in sarcopenia for cirrhotic patients.

Methods: Adult patients with clinically diagnosed liver cirrhosis who underwent at least 2 abdominal computed tomography (CT) scans in the hospital were enrolled. The interval between the two abdominal scans was 6 ± 1 months. Patients were categorized into persistent non-sarcopenia, new-onset sarcopenia, sarcopenia to non-sarcopenia, and persistent sarcopenia based on changes in sarcopenia. Kaplan-Meier method and Log-rank tests were used to separately compare unadjusted survival curves by different statuses of sarcopenia. Cox regression analysis was performed to assess the associations between different states of sarcopenia and overall mortality. The association between persistent non-sarcopenia and new-onset sarcopenia was analyzed by multivariate logistic regression analysis.

Results: A total of 307 patients were included for analysis. At the second assessment, 10.10% (31/307) patients were new-onset sarcopenia, 27.69% (85/307) with persistent sarcopenia status, while 13.03% (40/307) patients with sarcopenia developed non-sarcopenia and 49.19% (151/307) with persistent non-sarcopenia status. The overall survival rate was significantly lower in the persistent sarcopenia and new-onset sarcopenia than in the non-sarcopenia group and sarcopenia to non-sarcopenia group ( < 0.001). Persistent sarcopenia (HR 5.799, 95%CI 1.563-21.521, = 0.009) and new onset sarcopenia (HR 5.205, 95%CI 1.482-18.282, = 0.010) were identified as poor prognostic factors for cirrhotic patients. The etiology of cirrhosis and the initial skeletal muscle mass were independent risk factors for new-onset sarcopenia.

Conclusion: Sarcopenia is a dynamically changing process in patients with cirrhosis. Persistent and new-onset sarcopenia were independently and robustly associated with overall survival.

Citing Articles

A short-term predictive model for disease progression in acute-on-chronic liver failure: integrating spectral CT extracellular liver volume and clinical characteristics.

Xu Y, Li F, Liu B, Ren T, Sun J, Li Y BMC Med Imaging. 2025; 25(1):69.

PMID: 40033256 PMC: 11877947. DOI: 10.1186/s12880-025-01600-9.

References

Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, Hino K, Nishiguchi S . Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res. 2016; 46(10):951-63. DOI: 10.1111/hepr.12774. View

Chen L, Woo J, Assantachai P, Auyeung T, Chou M, Iijima K . Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020; 21(3):300-307.e2. DOI: 10.1016/j.jamda.2019.12.012. View

Boulhosa R, Lourenco R, Cortes D, Oliveira L, Lyra A, de Jesus R . Comparison between criteria for diagnosing malnutrition in patients with advanced chronic liver disease: GLIM group proposal versus different nutritional screening tools. J Hum Nutr Diet. 2020; 33(6):862-868. DOI: 10.1111/jhn.12759. View

Welch N, Dasarathy J, Runkana A, Penumatsa R, Bellar A, Reen J . Continued muscle loss increases mortality in cirrhosis: Impact of aetiology of liver disease. Liver Int. 2020; 40(5):1178-1188. PMC: 7195232. DOI: 10.1111/liv.14358. View

Roongpisuthipong C, Sobhonslidsuk A, Nantiruj K, Songchitsomboon S . Nutritional assessment in various stages of liver cirrhosis. Nutrition. 2001; 17(9):761-5. DOI: 10.1016/s0899-9007(01)00626-8. View

Carey E, Lai J, Wang C, Dasarathy S, Lobach I, Montano-Loza A . A multicenter study to define sarcopenia in patients with end-stage liver disease. Liver Transpl. 2017; 23(5):625-633. PMC: 5762612. DOI: 10.1002/lt.24750. View

Cruz-Jentoft A, Sayer A . Sarcopenia. Lancet. 2019; 393(10191):2636-2646. DOI: 10.1016/S0140-6736(19)31138-9. View

Selberg O, Selberg D . Norms and correlates of bioimpedance phase angle in healthy human subjects, hospitalized patients, and patients with liver cirrhosis. Eur J Appl Physiol. 2002; 86(6):509-16. DOI: 10.1007/s00421-001-0570-4. View

Juakiem W, Torres D, Harrison S . Nutrition in cirrhosis and chronic liver disease. Clin Liver Dis. 2013; 18(1):179-90. DOI: 10.1016/j.cld.2013.09.004. View

10.

Li Q, Zhang X, Tang M, Song M, Zhang Q, Zhang K . Different muscle mass indices of the Global Leadership Initiative on Malnutrition in diagnosing malnutrition and predicting survival of patients with gastric cancer. Nutrition. 2021; 89:111286. DOI: 10.1016/j.nut.2021.111286. View

11.

van Vugt J, Levolger S, de Bruin R, van Rosmalen J, Metselaar H, IJzermans J . Systematic Review and Meta-Analysis of the Impact of Computed Tomography-Assessed Skeletal Muscle Mass on Outcome in Patients Awaiting or Undergoing Liver Transplantation. Am J Transplant. 2016; 16(8):2277-92. DOI: 10.1111/ajt.13732. View

12.

Dasarathy S, Merli M . Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol. 2016; 65(6):1232-1244. PMC: 5116259. DOI: 10.1016/j.jhep.2016.07.040. View

13.

Bemeur C, Desjardins P, Butterworth R . Role of nutrition in the management of hepatic encephalopathy in end-stage liver failure. J Nutr Metab. 2011; 2010:489823. PMC: 3017957. DOI: 10.1155/2010/489823. View

14.

Mauro E, Crespo G, Martinez-Garmendia A, Gutierrez-Acevedo M, Diaz J, Saidman J . Cystatin C and Sarcopenia Predict Acute on Chronic Liver Failure Development and Mortality in Patients on the Liver Transplant Waiting List. Transplantation. 2020; 104(7):e188-e198. DOI: 10.1097/TP.0000000000003222. View

15.

Giusto M, Lattanzi B, Albanese C, Galtieri A, Farcomeni A, Giannelli V . Sarcopenia in liver cirrhosis: the role of computed tomography scan for the assessment of muscle mass compared with dual-energy X-ray absorptiometry and anthropometry. Eur J Gastroenterol Hepatol. 2015; 27(3):328-34. DOI: 10.1097/MEG.0000000000000274. View

16.

Yang Y, Da J, Yuan J, Zha Y . One-year change in sarcopenia was associated with cognitive impairment among haemodialysis patients. J Cachexia Sarcopenia Muscle. 2023; 14(5):2264-2274. PMC: 10570075. DOI: 10.1002/jcsm.13311. View

17.

Kumar V, Benjamin J, Shasthry V, Subramanya Bharathy K, Sinha P, Kumar G . Sarcopenia in Cirrhosis: Fallout on Liver Transplantation. J Clin Exp Hepatol. 2020; 10(5):467-476. PMC: 7527849. DOI: 10.1016/j.jceh.2019.12.003. View

18.

Bemeur C, Butterworth R . Reprint of: Nutrition in the Management of Cirrhosis and its Neurological Complications. J Clin Exp Hepatol. 2015; 5(Suppl 1):S131-40. PMC: 4442848. DOI: 10.1016/j.jceh.2015.02.004. View

19.

Tantai X, Liu Y, Yeo Y, Praktiknjo M, Mauro E, Hamaguchi Y . Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis. J Hepatol. 2021; 76(3):588-599. DOI: 10.1016/j.jhep.2021.11.006. View

20.

Sam J, Nguyen G . Protein-calorie malnutrition as a prognostic indicator of mortality among patients hospitalized with cirrhosis and portal hypertension. Liver Int. 2009; 29(9):1396-402. DOI: 10.1111/j.1478-3231.2009.02077.x. View